Sökning: onr:"swepub:oai:DiVA.org:liu-200753" > Minimal residual di...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04991naa a2200481 4500 | |
001 | oai:DiVA.org:liu-200753 | |
003 | SwePub | |
008 | 240207s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:154092187 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-2007532 URI |
024 | 7 | a https://doi.org/10.1002/cam4.66402 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1540921872 URI |
040 | a (SwePub)liud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Nahi, Harethu Linköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US,Karolinska Inst, Sweden4 aut0 (Swepub:liu)n/a |
245 | 1 0 | a Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma |
264 | 1 | b WILEY,c 2023 |
338 | a electronic2 rdacarrier | |
500 | a Funding Agencies|We would like to extend our gratitude to all patients and their families who participated in this study. Their willingness to contribute has been crucial for the continuation of our research. We would also like to acknowledge the invaluable work of our col | |
520 | a Background: The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression-free survival (PFS) and overall survival (OS).Methods: At our department, we recommend lenalidomide maintenance for patients who are MRD+ after ASCT, while MRD-negative (MRD-) patients, after information about the national guidelines, were not advised to follow this regimen.Results: Out of the total 228 patients, 175 received ASCT following first-line induction (MRD- 92 (53%), MRD+ 83 (47%), at 2 months post-ASCT), while 53 underwent ASCT after second-line treatment (MRD- 27 (51%), MRD+ 26 (49%), at the same time point). Comparatively, MRD- patients who did not receive maintenance demonstrated better OS than MRD+ patients who received upfront ASCT and maintenance treatment (96% vs. 86%, p = 0.030, at 3 years). However, nonsignificant difference was found in PFS (76% vs. 62%, at 3 years). Furthermore, second-line ASCT, MRD- non-maintained patients exhibited significantly better PFS than MRD+ (71% vs. 27%, p > 0.001, at 3 years). However, OS was better but nonsignificant (96% vs. 76%, at 3 years). Fluorescence in situ hybridization (FISH) analysis was performed on 141 out of the 228 patients. Of these, 85 (60%) patients were deemed standard risk (SR), and 56 (40%) were classified as high risk (HR). In the SR cohort, MRD- patients exhibited better PFS and OS than MRD+ patients (71% vs. 59% and 100% vs. 85%, respectively). In the HR cohort, the MRD- patients showed superior PFS but similar OS compared to MRD+ patients (66% vs. 42% and 81% vs. 80%, respectively).Conclusions: Our results indicate that being MRD- is a more crucial prognostic factor for the 3-year PFS and OS than the presence of high-risk cytogenetic markers or undergoing maintenance treatment. The latter appears insufficient, particularly for MRD+ patients following ASCT in the second-line setting, suggesting that these patients may require a more intensive treatment approach. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a minimum residual disease; multiple myeloma prognosis | |
700 | 1 | a Afram, Gabrielu Karolinska Inst, Sweden4 aut |
700 | 1 | a Uttervall, Katarinau Karolinska Institutet4 aut |
700 | 1 | a Lockmer, Sandrau Karolinska Inst, Sweden4 aut |
700 | 1 | a Tätting, Love,d 1988-u Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US4 aut0 (Swepub:liu)lovta16 |
700 | 1 | a Gahrton, Gostau Karolinska Institutet4 aut |
700 | 1 | a Kashif, Muhammadu Karolinska Institutet4 aut |
700 | 1 | a Alici, Evrenu Karolinska Institutet4 aut |
700 | 1 | a Stromberg, Olgau Dept Med, Sweden4 aut |
700 | 1 | a Klimkowska, Monikau Karolinska Institutet4 aut |
700 | 1 | a Lund, Johanu Karolinska Institutet4 aut |
710 | 2 | a Linköpings universitetb Institutionen för biomedicinska och kliniska vetenskaper4 org |
773 | 0 | t Cancer Medicined : WILEYg 12:22, s. 20736-20744q 12:22<20736-20744x 2045-7634 |
856 | 4 | u https://doi.org/10.1002/cam4.6640y Fulltext |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:1835835/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-200753 |
856 | 4 8 | u https://doi.org/10.1002/cam4.6640 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:154092187 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy